CiVi Biopharma to Participate in HC Wainwright BioConnect 2021 Conferences

CiVi Biopharma Resumes AURORA Phase 3 Clinical Trial of CIVI030 to Treat Systemic Sclerosis

CiVi Biopharma Announces Appointment of Shalom Jacobovitz as Chief Executive Officer

CiVi Biopharma Receives Worldwide Exclusive License to Develop a Novel, RNA Targeted Drug Against PCSK-9

CiVi Biopharma Raises $40 Million in Series A Financing From Boxer Capital of the Tavistock Group